Express Pharma

MoH&FW, DCG(I) grants approval to RMS Regrow for Chondron

4

Chondron ACI is indicated for the treatment of cartilage defects of the joints

Ministry of Health and Family Welfare (MoH&FW) and Drug Controller General India DCG(I) have granted market authorisation for Chondron ACI by Regenerative Medical Services Regrow. Chondron ACI is indicated for the treatment of cartilage defects of the joints. It uses the body’s own autologous cartilage cells which are cultured and multiplied for three to four weeks at Regrow’s Cell Processing Centre. The cultured cells are then implanted into the patient’s damaged joint leading to new cartilage regeneration, avoiding the need of early joint replacement.

Satyen Sanghavi, Chief Scientific officer and Executive Director, RMS Regrow said, “Chondron ACI has 97 per cent success rate with fast recovery, as observed in over four to five lakh cases performed worldwide. RMS Regrow is proud to announce the FDA approval for Chondron ACI and it is proprietary and patented by RMS Regrow.”

Chondron ACI is recommended for patients of 15-65 years age group. It is imperative for a patient to go through rehabilitation process for a minimum of six weeks. The rehabilitation process is performed in the guidance of the doctor and the physiotherapist. There is also medical insurance reimbursement available with Chondron ACI.

Comments are closed.